K2M Group Holdings, Inc. (NASDAQ:KTWO)‘s stock had its “buy” rating reissued by equities research analysts at Royal Bank Of Canada in a note issued to investors on Thursday. They presently have a $26.00 price target on the medical device company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 4.00% from the stock’s previous close.

A number of other research firms also recently issued reports on KTWO. BidaskClub raised shares of K2M Group Holdings from a “hold” rating to a “buy” rating in a research note on Wednesday. Cowen and Company reissued a “buy” rating and issued a $26.00 price target on shares of K2M Group Holdings in a research note on Wednesday. JMP Securities reissued an “outperform” rating and issued a $30.00 price target (up from $27.00) on shares of K2M Group Holdings in a research note on Wednesday, June 28th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of K2M Group Holdings in a research note on Thursday, June 22nd. Finally, TheStreet raised shares of K2M Group Holdings from a “d+” rating to a “c” rating in a research note on Monday, May 8th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $25.88.

Shares of K2M Group Holdings (NASDAQ KTWO) traded up 0.97% during mid-day trading on Thursday, hitting $25.00. The stock had a trading volume of 298,268 shares. The stock’s 50-day moving average is $23.57 and its 200 day moving average is $21.63. The firm’s market capitalization is $1.06 billion. K2M Group Holdings has a 1-year low of $15.45 and a 1-year high of $25.18.

K2M Group Holdings (NASDAQ:KTWO) last released its quarterly earnings results on Tuesday, May 2nd. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.02. K2M Group Holdings had a negative return on equity of 16.02% and a negative net margin of 17.48%. The company had revenue of $61.89 million during the quarter, compared to the consensus estimate of $60.10 million. Equities research analysts predict that K2M Group Holdings will post ($0.80) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/20/k2m-group-holdings-inc-nasdaqktwo-stock-rating-reaffirmed-by-royal-bank-of-canada.html.

In other K2M Group Holdings news, insider John Philip Md Kostuik sold 50,000 shares of the company’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $22.70, for a total value of $1,135,000.00. Following the sale, the insider now owns 199,107 shares in the company, valued at $4,519,728.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Gregory S. Cole sold 42,947 shares of the company’s stock in a transaction dated Friday, June 16th. The stock was sold at an average price of $22.80, for a total transaction of $979,191.60. Following the completion of the sale, the chief financial officer now owns 87,425 shares in the company, valued at approximately $1,993,290. The disclosure for this sale can be found here. In the last 90 days, insiders sold 95,805 shares of company stock worth $2,178,713. Corporate insiders own 5.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. Legal & General Group Plc boosted its stake in shares of K2M Group Holdings by 9.1% in the first quarter. Legal & General Group Plc now owns 6,763 shares of the medical device company’s stock worth $138,000 after buying an additional 564 shares during the period. Simplex Trading LLC purchased a new stake in K2M Group Holdings during the first quarter worth approximately $187,000. Parkwood LLC purchased a new stake in K2M Group Holdings during the first quarter worth approximately $223,000. Paradigm Capital Management Inc. NY purchased a new stake in K2M Group Holdings during the first quarter worth approximately $226,000. Finally, Trexquant Investment LP purchased a new stake in K2M Group Holdings during the first quarter worth approximately $250,000. Institutional investors and hedge funds own 98.75% of the company’s stock.

About K2M Group Holdings

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine and minimally invasive technologies and techniques. The Company’s solutions are focused on achieving three-dimensional Total Body Balance. Its spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor.

Analyst Recommendations for K2M Group Holdings (NASDAQ:KTWO)

Receive News & Ratings for K2M Group Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for K2M Group Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.